On November 12, 2024 mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Egis Pharmaceutical PLC, reported a new strategic license agreement for the commercialization of biosimilar candidates across key Central and Eastern European markets, including Hungary, Poland, Czech Republic, Slovakia, Romania, Bulgaria, Latvia, and Lithuania (Press release, mAbxience, NOV 12, 2024, View Source [SID1234648178]). The partnership also includes the option to expand to additional territories in the future.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, mAbxience will hold the marketing authorization for the biosimilars in these regions, while Egis will manage the commercialization and marketing activities. This collaboration underscores the commitment of both companies to broaden access to essential, high-quality therapies in markets where affordability and accessibility are critical.
José Ramón Millán, Global Partnering & Portfolio Director at mAbxience, commented on the partnership: "We are delighted to partner with Egis to bring our biosimilar candidate to patients in these important Eastern European markets. This agreement strengthens our presence in the region and reaffirms our dedication to ensuring that life-saving treatments are accessible and affordable. We look forward to working closely with Egis to make a significant impact on patient care."
Dr. Klara Marton, Business Development Director from Egis added: "This collaboration with mAbxience enables us to deliver high value treatments to patients across Central and Eastern Europe. We are proud to join forces with a trusted partner like mAbxience, whose commitment to high-quality, affordable healthcare solutions aligns with our mission to improve patient access and patient outcomes in our region."
This agreement marks a significant milestone in mAbxience’s expansion into new markets and further reinforces its commitment to providing accessible, high-quality biosimilar therapies to patients worldwide.